Morwak 250mgg, 500mg,750mg Tablets

1. Short term use in the treatment of hyphaema and in patients with established coagulopathies who are undergoing minor surgery.

2. Management of dental extraction in haemophiliacs.

3. Hereditary angioedema.

4. Menorrhagia.

MOR WAK is contraindicated in:

• patients who are hypersensitive to tranexamic acid or to any of the excipients of MOR WAK (see COMPOSITION).
• history of acute venous or arterial thrombosis.
• patients who suffer from massive urinary tract haemorrhage.
• severe renal impairment because of risk of accumulation.
• active thromboembolic disease.
• fibrinolytic conditions following consumption coagulopathy except in those with predominant activation of the fibrinolytic system with acute severe bleeding.
• history of convulsions.

MOR WAK is not recommended in patients suffering massive haematuria from the upper urinary tract (especially haemophilia) as ureteric obstruction has been reported occasionally (see CONTRAINDICATIONS).

Care should be taken:

• when prescribing MOR WAK to patients with renal insufficiency because of the risk of accumulation (see CONTRAINDICATIONS);
• when disseminated intravascular coagulation is in progress; Regular eye examination (e.g. visual acuity, slit lamp, intra-ocular pressure, visual fields) and liver function tests should be undertaken during long-term treatment of patients with hereditary angioedema. Dosages should be reduced in patients with renal impairment. (See DOSAGE AND DIRECTIONS FOR USE).

Medicines with actions on haemostasis should be given with caution to patients on antifibrinolytic therapy such as MOR WAK. The potential for thrombus formation may be increased by oestrogens, for example, or the action of the fibrinolytic antagonised by compounds such as the thrombolytic. Concomitant chlorpromazine and tranexamic acid, as in MOR WAK, therapy of subarachnoid haemorrhage has been reported to result in cerebral vasospasm and cerebral ischemia, and possibly a reduction in cerebral blood flow. It is not recommended to use MOR WAK concomitantly with highly activated prothrombin products.

The safety of MOR WAK in pregnant and lactating women has not been established. MOR WAK passes into breast milk to a concentration of approximately one hundredth of the concentration in the maternal blood. Caution should be exercised when MOR WAK is given to lactating women.

Immune system disorders

Less frequent: Hypersensitivity reactions including anaphylaxis

Nervous System Disorders

Less frequent: Convulsions, particularly in case of misuse

Eye disorders

Less frequent: Visual disturbances including impaired colour vision, retinal vein/artery occlusion

Vascular disorders

Less frequent: Thromboembolic events, malaise with hypotension, with or without loss of consciousness (generally following a too fast intravenous injection, exceptionally after oral administration), arterial or venous thrombosis at any sites

Gastrointestinal disorders

Frequent: Nausea, vomiting, diarrhoea

Skin and subcutaneous tissue disorders

Less frequent: Allergic skin reactions

Symptoms of overdose may be nausea, vomiting, orthostatic symptoms and/or hypotension. Initiate vomiting, then charcoal therapy. Maintain a high fluid intake to promote renal excretion.